GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (ASX:ME1DE) » Definitions » Price-to-Owner-Earnings

Melodiol Global Health (ASX:ME1DE) Price-to-Owner-Earnings : (As of Jun. 09, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Melodiol Global Health Price-to-Owner-Earnings?

As of today (2024-06-09), Melodiol Global Health's share price is A$0.39. Melodiol Global Health does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Melodiol Global Health's Price-to-Owner-Earnings or its related term are showing as below:


ASX:ME1DE's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.31
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-09), Melodiol Global Health's share price is A$0.39. Melodiol Global Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-11.28. Therefore, Melodiol Global Health's PE Ratio for today is At Loss.

As of today (2024-06-09), Melodiol Global Health's share price is A$0.39. Melodiol Global Health's EPS without NRI for the trailing twelve months (TTM) ended in was A$-6.00. Therefore, Melodiol Global Health's PE Ratio without NRI for today is At Loss.


Melodiol Global Health Price-to-Owner-Earnings Historical Data

The historical data trend for Melodiol Global Health's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health Price-to-Owner-Earnings Chart

Melodiol Global Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Melodiol Global Health Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Melodiol Global Health's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Melodiol Global Health's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Melodiol Global Health's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Melodiol Global Health's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Melodiol Global Health's Price-to-Owner-Earnings falls into.



Melodiol Global Health Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Melodiol Global Health's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.39/-11.35
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Melodiol Global Health  (ASX:ME1DE) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Melodiol Global Health Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Melodiol Global Health (ASX:ME1DE) Business Description

Traded in Other Exchanges
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (ASX:ME1DE) Headlines

No Headlines